My Tree has launched a Memorial Park in the UK that enables people to plant a tree with the ashes of their loved one. It is the sole exclusive UK memorial park which offers ashes burial with the planting of a tree. The company is in discussion with DoubleTree Hilton and First Funerals. My Tree has launched its first park five miles outside of Reading and 38 miles from London. The company will use the funds to promote the site, do pre-planting to maximize usage of space and support plans to open more sites by the end of 2020.
days to go:
Expired
investment:
£160,380
Gravitricity has invented an uncommon technology which will use massive weights to collect energy underground. The company aims to be very cost-effective and have no standing losses, no explosive materials and no parasitic loads. Gravitricity has created a 250kW Concept Demo and a modular full-scale system and, It has worked with Glasgow-based controls-partner ISC and Dutch winch partner Huisman Equipment BV. With the proceeds, the company will develop the Concept Demo, the detailed design of the modular full-scale system and improve Europe and South Africa's projects plans.
days to go:
Expired
investment:
£759,700
GiftRound is a hassle-free and secure online platform that comes with 250 successful gift collections with nearly 3000 contributions. This platform allows a cash-free solution where there is a hassle of sharing your personal banking information. GiftRound is 100% free to use and generates its revenue when customers purchase gifts, gift vouchers or experiences from quality retailers that GiftRound has a relationship with. GiftRound aims to change the way people collect money for gifts both in the workplace and with friends & family. With the proceeds, the company aims to integrate a GiftRound Store to give customers a seamless experience. The company will also grow its brand presence and reputation for quality service for everyone that wants to group collect money for a gift.
days to go:
Expired
investment:
£30,670
TC BioPharm is an immunotherapy company. It has used its patented technology to harness the power of a particular part of the immune system, Gamma Delta T-cells (GDT), to negate cancer cells in the human body. TC BioPharm has treated terminally ill patients with acute myeloid leukaemia in approved clinical trials garnering positive responses from multiple patients. The company has received regulatory approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to run a COVID-19 clinical trial to address the global pandemic. TC BioPharm aims to use its current technology to provide a frozen product that can be manufactured cost-effectively and distributed globally. The company has already raised over £7 million in the last 15 months. It will use the investment to take its clinical trials forward in COVID-19 and cancer.
days to go:
Expired
investment:
£1,753,067
Scribestar's Software-as-a-Service (SaaS) platform digitises and automates the documentation and compliance processes required for raising capital on stock markets such as IPOs, bonds etc. The platform intends to provide users with structured data format documents that can be machine-read and monetised. Scribestar aims to become a contender in the $22 billion Regulatory/Legal Technology markets. It argues that it is already active in the UK and has witnessed over 50 transactions on its system. It is also a part of the London Stock Exchange Issuer Services and CMS equIP with 4 years of verifiable commercial use and over £13 million received as investments. Scribestar asserts that its services are being regularly used by three law firms in the UK with more showing interest in its capability to function as a remote tool to manage the compliance documentation process. The company will use the investment to start its expansion in the US and other markets targeting law firms and deliver successful trials with stock exchanges.
days to go:
Expired
investment:
£864,009
Crosspay is a company that aims to make remittance simpler and cheaper. The company built its proprietary system in 2017 to bolster international transfers at a fraction of the money charged by traditional Over-The-Counter (OTC) services. It has since powered over 50,000 transactions across 50 countries with a cumulative value of approx £32,350,000. The company aspires to become the segment leader in the more than $200 billion global remittance market. Crosspay was rated 'Excellent' on Trustpilot. It also created white-labelled apps for charities and churches to host content, broadcast live and receive donations simultaneously, irrespective of location. The company has been invited to partner on an Innovate UK project. It will use the investment to grow its business across different verticals.
days to go:
Expired
investment:
£212,581
Sendit.Money is a remittance entity. It argues that individuals sending or receiving money in emerging markets can face insecure processes, slow transaction times and incur high costs. Sendit.Money asserts that this is because non-fiat currencies are changed multiple times before they are received. The company aims to change this. Its prototype application for African markets was received amidst positive feedback. It is now building a cost-effective mobile wallet providing a secure and inexpensive way to send and receive money that also allows users to compare transfer fees of different remittance agents in real-time. Sendit.Money was shortlisted as Best Global start-up at the 2020 Wales Startup Awards. The company will build and launch its Most Valuable Product (MVP) in Q3 of 2021. It will also use the funding to begin work with an authorised entity to become an approved representative.
days to go:
Expired
investment:
£182,732
C-Major is a medical technology company. It asserts that over 2 million people suffer a Needle Stick Injury (NSI) every year and are at risk of contracting blood-borne viruses such as Hepatitis and HIV. It aspires to resolve this crisis by bringing to market its patented medical device, Controlled Helical Retraction Device, to prevent NSIs. The company argues that the device contains a ‘Helical Track’ mechanism for controlled acceleration of the needle during retraction as well as a ‘Sealed Port’ to minimise any blood splatter. C-Major endeavours to disrupt the $5.5 billion safety syringe market with its product. It is backed by the UK 'Innovation Seed' fund. C-Major will use the investment to complete the final design of its product for manufacture and assembly ahead of a Series A funding round in 2021.
days to go:
Expired
investment:
£211,595
Anastasis Biotec (AB) is a company that is developing a human protein-based product, Syntana-4 (S-4), that inhibits Cancer Stem Cells (CSC) - the growth engine of cancer. The global cancer drug market was at ~$200 billion in 2019. S-4 will initially target use for patients with relapsed prostate cancer which caused 3.8% of global cancer deaths in 2018. The company asserts that S-4 will have low manufacturing costs, making it affordable, enabling ‘mass-market’ sales. AB has raised £450,000 in equity convertible loans and grants in 2019 & 2020, including an Innovate-UK award. It is also aiming to progress S-4 further in collaboration with the University of Chicago’s cancer stem cell therapeutics Research and development (R&D) program. The company will use the investment to complete lab-testing before starting clinical trials.
days to go:
Expired
investment:
£270,543
Wombat is an investment platform that encourages millenials in the UK, Europe and beyond to invest in some of the world’s best-known brands for as little as £10. Their mission is to empower the generation of millenials to manage, save and grow money by breaking down barriers to traditional investing. The Wombat app was launched in the summer of 2019, and the company has already acquired more than 5,000 customers. Moreover, the company was nominated as Best Newcomer for the Robo Investing Awards and received positive press coverage. With the proceeds, Wombat is planning to build a strong customer base, fulfil growth strategy with a significant increase in marketing, product development, and to educate customers about investing.
days to go:
Expired
investment:
£435,717
